Glioblastoma is the most frequent primary malignant brain tumour in adults. Methylation of the O-6-methylguanine-DNA methyltransferase (MGMT) promoter is of prognostic as well as of predictive value, as patients with MGMT promoter methylation survive longer and have better responses to the alkylating chemotherapeutic agent temozolomide. The current first-line therapy approaches after maximum safe resection include radiochemotherapy with temozolomide, radiochemotherapy with the combination of temozolomide and lomustine (CCNU), as well as tumour treating fields. Currently several early clinical studies investigate new treatment possibilities in glioblastoma.
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